Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of “Hold” from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given an average rating of “Hold” by the twenty-one research firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell rating, twelve have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $36.8571.

Several equities analysts recently weighed in on the stock. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Morgan Stanley increased their price target on shares of Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. UBS Group reduced their price target on shares of Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, October 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Finally, Cowen initiated coverage on shares of Moderna in a research report on Sunday, July 13th. They set a “hold” rating for the company.

Moderna Stock Performance

MRNA opened at $27.16 on Monday. The firm has a market cap of $10.61 billion, a P/E ratio of -3.61 and a beta of 2.02. The firm has a 50-day moving average of $25.86 and a 200 day moving average of $27.18. Moderna has a fifty-two week low of $23.15 and a fifty-two week high of $56.69.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm’s revenue for the quarter was down 41.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.33) earnings per share. Equities research analysts predict that Moderna will post -9.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Moderna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Moderna by 3.2% during the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after purchasing an additional 1,312,192 shares during the period. Geode Capital Management LLC boosted its position in Moderna by 19.1% during the second quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after purchasing an additional 1,420,690 shares during the period. Theleme Partners LLP boosted its position in Moderna by 8.6% during the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock worth $217,100,000 after purchasing an additional 626,420 shares during the period. Invesco Ltd. boosted its position in Moderna by 20.7% during the second quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock worth $195,917,000 after purchasing an additional 1,217,408 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Moderna by 0.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company’s stock worth $101,982,000 after purchasing an additional 11,270 shares during the period. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.